KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Operating Income (2016 - 2025)

Sarepta Therapeutics (SRPT) has 14 years of Operating Income data on record, last reported at $161.7 million in Q4 2024.

  • For Q4 2024, Operating Income rose 556.57% year-over-year to $161.7 million; the TTM value through Dec 2024 reached $218.1 million, up 181.43%, while the annual FY2024 figure was $218.1 million, 181.43% up from the prior year.
  • Operating Income reached $161.7 million in Q4 2024 per SRPT's latest filing, up from $22.2 million in the prior quarter.
  • Across five years, Operating Income topped out at $161.7 million in Q4 2024 and bottomed at -$211.1 million in Q2 2022.
  • Average Operating Income over 5 years is -$80.5 million, with a median of -$112.4 million recorded in 2020.
  • Peak YoY movement for Operating Income: plummeted 281.2% in 2022, then soared 556.57% in 2024.
  • A 5-year view of Operating Income shows it stood at -$170.7 million in 2020, then soared by 38.02% to -$105.8 million in 2021, then dropped by 0.96% to -$106.8 million in 2022, then soared by 123.05% to $24.6 million in 2023, then skyrocketed by 556.57% to $161.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Operating Income were $161.7 million in Q4 2024, $22.2 million in Q3 2024, and -$701000.0 in Q2 2024.